Clinical outcomes in patients with DLBCL treated with R-CHOP according to radiotherapy and interim PET response

Data from a retrospective study of patients with DLBCL treated with R-CHOP, stratified by interim PET response and radiotherapy administration, showed that patients who had achieved a metabolic complete response exhibited superior overall survival, recurrence-free survival, and freedom from disease progression (FFDP) compared with the patients in the metabolic PR (mPR) group (p=0.003, p=0.001, and p=0.008, respectively). Further, FFDP in the mPR group without radiotherapy was significantly lower than that of the other groups (mCR with/without radiotherapy and mPR with radiotherapy; p=0.001).